Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

ImageneBio, Inc. IMA

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$800,000
▼ 77.1% YoY
$-45.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 800,000.00
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.8 · Net income -45.3
15.0M30.0M-25.0M-50.0M
202020232025
Compound annual growth
−62.9%
−38.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −38.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -6056.4% · Net ·
-2000%-4000%-6000%
202020222025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -80.2
-30M-60M
202020222025
Net buybacks $M Dividends $M
FY2023 · Dividends · · Net buybacks -36.8
-15M-30M
2023

Total assetsUSD 153.0M
EquityUSD 133.1M
CashUSD 94.5M
Gross debtUSD 0.00
Net debtUSD -94.5M
Current ratio12.49×

The company holds more cash than debt.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
IMA, 6-year financial record
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.1−0.1−0.0−0.0
EBITDA $B−0.0−0.0−0.1−0.1−0.0−0.0
Income tax $B−0.00.0−0.00.00.0◌
Net income $B−0.0−0.0−0.1−0.1−0.0−0.0
Free cash flow $B◌◌−0.1−0.1−0.1−0.0
EPS, diluted $−9.64−22.10−1.63−1.90−1.22−16.00
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %———−38.8——
Shares out B◌0.050.050.040.040.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 1 failure · 1 divergence in 24 reconciliationsAUDITED

Reconciled in 4 of the 6 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure1 divergent
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2020

Share this section

Download image